Fairmount Funds Management LLC
WEST CONSHOHOCKEN, PA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.59B2026 Q3
Positions12
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.97.5%
What Changed This Quarter?
Top Holdings
ORKA
Oruka Therapeutics
19.4%
KRSA
Korsana Biosciences
18.3%
DNTH
Dianthus Therapeutics
14.0%
DMRA
Damora Therapeutics
11.6%
COGT
Cogent Biosciences
11.1%
VRDN
Viridian Therapeutics
6.6%
ELVN
Enliven Therapeutics
5.3%
JBIO
Jade Biosciences
4.0%
New / Increased
2 new · 2 increased
KRSANEW
Korsana Biosciences
18.3%
DMRANEW
Damora Therapeutics
11.6%
CBIO
Crescent Biopharma
3.3%
+31.1%
ZBIO
Zenas Biopharma
4.0%
+0.5%
Reduced / Exited
0 reduced · 2 sold out
Damora Therap…EXIT
Damora Therapeutics
15.0%
Apogee Therap…EXIT
Apogee Therapeutics
2.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.